Survodutide
Survodutide (BI 456906) is a GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Administered once weekly by subcutaneous injection, survodutide has demonstrated exceptional weight loss of up to 18.7% and significant liver fat reduction in Phase 2 trials, with particular promise for obesity and MASH/NASH.
Survodutide (BI 456906) is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist co-developed by Boehringer Ingelheim and Zealand Pharma. Based on an oxyntomodulin backbone, survodutide is designed to combine the appetite-suppressing and glucose-lowering effects of GLP-1 receptor activation with the energy expenditure-enhancing and hepatic fat-reducing effects of glucagon receptor activation.
Overview
Survodutide was designed by Zealand Pharma using their peptide engineering platform and is being developed in partnership with Boehringer Ingelheim. The compound is an acylated peptide analog of oxyntomodulin, the endogenous hormone produced by intestinal L-cells that naturally activates both GLP-1 and glucagon receptors. Through targeted amino acid substitutions and fatty acid acylation, survodutide achieves the extended half-life necessary for once-weekly dosing while maintaining potent dual receptor agonism.
What distinguishes survodutide within the metabolic drug landscape is its exceptional Phase 2 weight loss efficacy and its strong profile in liver fat reduction. The Phase 2 trial in obesity reported up to 18.7% body weight loss at 46 weeks — among the highest ever reported for a non-surgical, single-agent intervention. Additionally, Phase 2 data in MASH patients demonstrated substantial improvements in liver histology, positioning survodutide as a leading candidate for an indication with no approved pharmacotherapy as of early 2025 (resmetirom received FDA approval for MASH in March 2024, becoming the first).
Boehringer Ingelheim has initiated Phase 3 trials for both obesity and MASH, reflecting confidence in survodutide's differentiated profile compared to pure GLP-1R agonists.
Mechanism of Action
Survodutide produces its metabolic effects through simultaneous engagement of two receptor systems:
GLP-1 Receptor Agonism: Survodutide potently activates GLP-1 receptors throughout the body. In the pancreas, this drives glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon release from alpha cells. In the brain, GLP-1R activation in the hypothalamic arcuate nucleus, paraventricular nucleus, and hindbrain (nucleus tractus solitarius, area postrema) reduces appetite, food cravings, and overall caloric intake. In the GI tract, GLP-1R activation delays gastric emptying, contributing to postprandial glucose control and satiety.
Glucagon Receptor Agonism: The glucagon component of survodutide activates hepatic glucagon receptors, stimulating fatty acid beta-oxidation, ketogenesis, and energy expenditure through thermogenesis. Glucagon receptor signaling promotes amino acid catabolism and increases resting metabolic rate. In adipose tissue, glucagon receptor activation promotes lipolysis. The net effect is increased total energy expenditure that complements the reduced energy intake mediated by GLP-1R agonism.
Enhanced Hepatic Fat Clearance: The glucagon receptor-mediated increase in hepatic fatty acid oxidation is the primary mechanism driving survodutide's exceptional liver fat reduction. By simultaneously reducing de novo lipogenesis (via improved insulin sensitivity from GLP-1R agonism) and increasing fatty acid oxidation (via GCGR agonism), survodutide addresses hepatic steatosis from both directions. This dual approach produces liver fat reductions that substantially exceed those of selective GLP-1R agonists.
Balanced Glycemic Effect: The hyperglycemic potential of glucagon receptor activation is counterbalanced by the insulin-stimulating and glucagonostatic effects of GLP-1R agonism. In clinical trials, survodutide reduces HbA1c in diabetic patients and does not cause hyperglycemia in non-diabetic individuals, demonstrating that the dual agonism is metabolically balanced.
Cardiovascular and Lipid Effects: Beyond weight loss and glycemic control, the glucagon component may provide additional cardiovascular benefits through improved lipid metabolism. Glucagon receptor activation reduces circulating LDL cholesterol and triglycerides and may improve HDL cholesterol, complementing the cardiovascular benefits of GLP-1R-mediated weight loss.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Phase 2 Weight Loss
The Phase 2 trial of survodutide in adults with overweight or obesity demonstrated exceptional weight loss across dose levels over 46 weeks. At the highest dose (4.8 mg weekly), participants achieved a mean body weight reduction of 18.7% from baseline, compared to 2.1% with placebo. Lower doses also produced clinically meaningful weight loss: 2.4 mg weekly achieved approximately 13%, and 3.6 mg weekly achieved approximately 15%. These results place survodutide among the most effective weight loss agents ever evaluated in clinical trials, approaching the efficacy of tirzepatide at its highest dose. Importantly, weight loss trajectories had not fully plateaued at 46 weeks, suggesting potential for further reductions with extended treatment. Blueher, M. et al. (2024) — Lancet Diabetes Endocrinol.
Comparison with Other Metabolic Therapies
Survodutide's 18.7% weight loss at 46 weeks compares favorably with semaglutide 2.4 mg (14.9% at 68 weeks in STEP 1) and approaches tirzepatide 15 mg (22.5% at 72 weeks in SURMOUNT-1). However, direct head-to-head comparisons have not been conducted, and differences in trial populations, duration, and design limit cross-trial comparisons. Survodutide's particular strength appears to be in liver fat reduction and MASH, where its Phase 2 histological outcomes are among the strongest reported for any agent.
Liver Fat Reduction
Across clinical trials, survodutide has consistently demonstrated dramatic reductions in liver fat content. MRI-PDFF assessments show 60-87% relative reductions in hepatic fat fraction from baseline, with many patients achieving normal liver fat levels (<5% by MRI-PDFF). This exceeds the typical 30-50% liver fat reduction observed with selective GLP-1R agonists like semaglutide, supporting the hypothesis that the glucagon receptor component provides additive hepatic fat clearance through direct stimulation of hepatic fatty acid oxidation.
Type 2 Diabetes
In patients with type 2 diabetes, survodutide has demonstrated robust glycemic improvements alongside weight loss. Phase 2 data showed HbA1c reductions of 1.5-2.0% from baseline at therapeutic doses, with a substantial proportion of patients achieving HbA1c targets below 7%. The glycemic efficacy confirms that despite the glucagon component's potential to raise blood glucose, the GLP-1R agonism dominates glycemic control. Weight loss in the T2D population was somewhat lower than in the non-diabetic obesity population, consistent with observations across the GLP-1R agonist class. Nauck, M. A. et al. (2024) — Lancet Diabetes Endocrinol.
MASH/NASH (Phase 2)
The Phase 2 trial in patients with biopsy-confirmed MASH (non-cirrhotic, with fibrosis stages F1-F3) yielded highly promising results. At 48 weeks, survodutide demonstrated significant improvements in liver histology. Approximately 47-64% of patients on survodutide (dose-dependent) achieved the primary endpoint of MASH resolution without worsening of fibrosis, compared to 14% with placebo. Additionally, 36-52% achieved fibrosis improvement by at least one stage without worsening of MASH. Liver fat content assessed by MRI-PDFF decreased by 60-87% from baseline at therapeutic doses. These results represent some of the strongest histological outcomes reported for any MASH therapy. Sanyal, A. J. et al. (2024) — N. Engl. J. Med.
Safety Profile
In Phase 2 trials, survodutide's adverse event profile is dominated by gastrointestinal symptoms consistent with GLP-1R agonist pharmacology. Nausea occurred in 28-41% of participants (dose-dependent), diarrhea in 13-22%, vomiting in 9-20%, and constipation in 8-13%. Most GI events were mild to moderate in severity and occurred primarily during dose escalation periods. Treatment discontinuation due to adverse events ranged from 8-16% across dose groups. Heart rate increases of 3-6 bpm were observed at therapeutic doses, consistent with the GLP-1R agonist class. Transient, mild elevations in liver transaminases (ALT, AST) were seen in a minority of participants, likely related to hepatic fat mobilization and remodeling rather than drug-induced liver injury. No pancreatitis or medullary thyroid carcinoma signals were detected. There were no clinically significant episodes of hyperglycemia attributed to the glucagon receptor component, confirming appropriate GLP-1/glucagon receptor balance.
Pharmacokinetic Profile
Survodutide — Pharmacokinetic Curve
Subcutaneous injection (once weekly)Ongoing & Future Research
- Phase 3 SYNCHRONIZE (obesity): Global registrational trials evaluating survodutide for weight management in adults with obesity, with results expected 2026-2027.
- Phase 3 ESSENCE (MASH): Registrational trials evaluating survodutide for histological improvement in MASH, one of the most anticipated liver disease programs in development.
- Cardiovascular outcomes: A dedicated CVOT is planned or anticipated to evaluate MACE reduction, leveraging the cardiovascular benefits of substantial weight loss and improved lipid metabolism.
- Combination with resmetirom: Boehringer Ingelheim has expressed interest in combination approaches for MASH. Survodutide plus resmetirom (the first approved MASH drug) is a logical pairing.
- Cirrhotic MASH: Future studies may evaluate efficacy in compensated cirrhosis (F4 fibrosis), an underserved population.
- Pediatric/adolescent obesity: Potential future development for younger populations with severe obesity.
- Renal outcomes: The class effect of GLP-1R agonists on renal function, combined with potential glucagon-mediated renal hemodynamic effects, warrants dedicated investigation.
Quick Start
- Typical Dose
- 0.6mg starting, titrate up to 3.6-6.0mg weekly
- Frequency
- Once weekly (same day each week)
- Route
- Subcutaneous injection (once weekly)
- Cycle Length
- 24-76+ weeks continuous therapy
- Storage
- Reconstituted: 2-8°C immediately after mixing
Molecular Structure
- Formula
- Proprietary (acylated peptide)
- Weight
- Not publicly disclosed Da
- Length
- 29 amino acids
- CAS
- 2375697-36-2
- PubChem CID
- 163321850
- Exact Mass
- 404.2083 Da
- LogP
- 7.4
- TPSA
- 57.5 Ų
- H-Bond Donors
- 2
- H-Bond Acceptors
- 3
- Rotatable Bonds
- 3
- Complexity
- 630
Identifiers (SMILES, InChI)
InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)/i5+1,6+1,12+1,22+1,24+1,25+1
LDGIHZJOIQSHPB-NCYGBWEDSA-NResearch Indications
Weight Loss
14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
Dual mechanism addresses both energy intake and expenditure.
Metabolic
62% achieved MASH improvement without fibrosis worsening at 4.8mg.
63-67% achieved ≥30% liver fat reduction.
HbA1c reduction up to -1.6% at highest doses.
Research Protocols
subcutaneous Injection
Subcutaneous injection to abdomen (2+ inches from navel), upper thigh, or upper arm. Any time of day, with or without food.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | —(Route: SubQ) |
| Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | —(Route: SubQ) |
| MASH Treatment | 2.4-4.8mg | Once weekly | —(Route: SubQ) |
| Type 2 Diabetes | 0.3-2.7mg | Once weekly | —(Route: SubQ) |
Reconstitution Guide (mg vial + mL BAC water)
- Remove vial from refrigerator; allow 15-30 minutes to reach room temperature
- Clean rubber stoppers with alcohol swabs
- Draw prescribed amount of bacteriostatic water
- Insert needle at 45-degree angle into vial
- Inject BAC water down vial side slowly to minimize foaming
- Gently swirl (do not shake vigorously)
- Allow 2-3 minutes for complete dissolution
- Solution should be clear to slightly opalescent without particles
- Store reconstituted solution in refrigerator immediately
Interactions
Peptide Interactions
This exceeds the typical 30-50% liver fat reduction observed with selective GLP-1R agonists like semaglutide, supporting the hypothesis that the glucagon receptor component provides additive hepatic fat clearance through direct stimulation of hepatic fatty acid oxidation.
This exceeds the typical 30-50% liver fat reduction observed with selective GLP-1R agonists like semaglutide, supporting the hypothesis that the glucagon receptor component provides additive hepatic fat clearance through direct stimulation of hepatic fatty acid oxidation.
Survodutide's 18.7% weight loss at 46 weeks compares favorably with semaglutide 2.4 mg (14.9% at 68 weeks in STEP 1) and approaches tirzepatide 15 mg (22.5% at 72 weeks in SURMOUNT-1). However, direct head-to-head comparisons have not been conducted, and differences in trial populations, duration...
What to Expect
What to Expect
Possible nausea, reduced appetite (most common during escalation)
Initial weight loss begins; improved satiety between meals
Progressive weight loss; potential energy level improvements
Approaching steady-state; more consistent effects
Sustained weight loss; average 15-19% by week 46
Safety Profile
Common Side Effects
- Nausea (40-66%)
- Diarrhea (25-49%)
- Vomiting (15-41%)
- Slight heart rate increase (mean 2-5 bpm)
Contraindications
- Not recommended in pregnancy or breastfeeding
- Use contraception during treatment
Discontinue If
- Severe persistent nausea/vomiting preventing oral intake
- Signs of pancreatitis (severe abdominal pain radiating to back)
- Allergic reactions (rash, itching, difficulty breathing)
- Severe hypoglycemia with insulin/sulfonylureas
- Gallbladder symptoms (right upper quadrant pain)
- Significant tachycardia or arrhythmias
Quality Indicators
What to look for
- Clear to slightly opalescent solution without visible particles
- Sealed vial with intact rubber stopper
- Within expiration date
Caution
- Slight foam after reconstitution is normal if disappears within minutes
Red flags
- Cloudy solution or visible particles indicates contamination
- Discoloration of powder or solution
Frequently Asked Questions
References (9)
- [1]
- [2]Phase 2 MASH and Fibrosis Trial (2024)
- [3]Phase 2 Type 2 Diabetes Trial (2023)
- [4]Preclinical Pharmacology Study (2022)
- [7]
- [8]Eriksson, O. et al Glucagon receptor occupancy of survodutide by PET imaging Diabetes Obes. Metab. (2023)
- [9]
- [6]Sanyal, A. J. et al Survodutide for MASH N. Engl. J. Med. (2024)
- [5]
Super Shred (AOD-9604 + CJC-1295 + Ipamorelin)
The Super Shred blend is a compounded three-peptide fat loss stack combining AOD-9604 (anti-obesity GH fragment), CJC-1295 (GHRH analog), and Ipamorelin (GH secretagogue). The protocol targets body recomposition through direct lipolytic action and enhanced growth hormone secretion for simultaneous fat loss and lean mass preservation.
Svetinorm
Svetinorm is a complex peptide bioregulator preparation derived from liver tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for hepatoprotective research, liver aging, and restoration of hepatic function. Part of the Cytomed line of tissue-specific bioregulators.